Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Abstract

Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 5, and 7F. Our data do not support or exclude cross-protection against serotype 19A.

Keywords: 10-valent pneumococcal conjugate vaccine; 7-valent pneumococcal conjugate vaccine; IPD; PCV10; PCV7; Streptococcus pneumoniae; incidence; invasive pneumococcal disease; streptococci; surveillance; the Netherlands; vaccine switching.

Figure 1

Age-specific incidence of invasive pneumococcal disease caused by any serotype of Streptococcus pneumoniae per epidemiologic year (June–May), the Netherlands. Vertical dashed lines indicate introduction of 7-valent pneumococcal conjugate vaccine in June 2006 and 10-valent pneumococcal conjugate vaccine in May 2011. Incidences are based on sentinel surveillance data and extrapolated to the national level.

Figure 2

Age-specific incidence of invasive pneumococcal disease caused by different Streptococcus pneumoniae serotypes per epidemiologic year (June–May), the Netherlands. A) 7-valent pneumococcal conjugate vaccine (PCV7) serotypes; B) non-PCV7 serotypes; C) PCV10–7 pneumococcal conjugate vaccine serotypes, D) non-PCV10 serotypes; and E) serotype 19A. Vertical dashed lines indicate introduction of PCV7 in June 2006 and PCV10 in May 2011. Incidences are based on sentinel surveillance data and extrapolated to the national level.